Q-omics provides the consensus-scored HLA-E profile across patient tissues and cancer cell-line models. HLA-E expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HLA-E is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, HLA-E RNA expression shows 16,922 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, LUAD, and LSCC as cancer lineages where HLA-E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HLA-E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HLA-E survival associations across molecular data types. HLA-E RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HLA-E RNA expression–survival associations across cancer types. High HLA-E expression shows unfavorable associations in UVM and KIRP, but favorable associations in SKCM, KIRC, MESO and LIHC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for HLA-E RNA expression.
This table summarizes HLA-E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HLA-E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HLA-E shows lower tumor expression in LUAD, KICH and LUSC and higher tumor expression in KIRC, HNSC and LIHC. The LUAD box plot shows higher HLA-E RNA expression in normal versus tumor tissue (log2 FC = −1.738, t-test p < 0.001).
This table shows molecular features associated with HLA-E in patient tissues and cancer cell lines. In patient samples, HLA-E shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HLA-E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
